Toki Fillman

Toki Fillman


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in The Journal of Pediatrics
Verified
Journal Article
Closed access
TFToki Fillman
Toki Fillman
JMJamie Matteson
Jamie Matteson
HTHao Tang
Hao Tang
DMDeepika Mathur
Deepika Mathur
RZRana Zahedi
Rana Zahedi
SSStanley Sciortino
Stanley Sciortino

30 October 2025 in Journal of Exposure Science & Environmental Epidemiology
Verified
Journal Article
Open access
PDF file
TFToki Fillman
Toki Fillman
SCScott Coffin
Scott Coffin
BTBrandon Ta
Brandon Ta
EBEmily Beglarian
Emily Beglarian
WLWendy Linck
Wendy Linck
KAKathleen Attfield
Kathleen Attfield
Background Studies from areas with high level per- and polyfluoroalkyl substance (PFAS) contamination have reported significant contributions of drinking water to overall exposure but few studies have focused on general populations. Objective To examine the association between PFAS in public water system drinking water and concentrations in serum among a general population of California adults. Methods The CARE (California Regional Exposure) biomonitoring study measured PFAS in serum of Southern and Eastern California adults between 2018 and 2020. Participant addresses were geocoded and geographically assigned to public water systems (PWS). Between 2019 and 2022, the California State Water Resources Control Board issued investigative PFAS monitoring orders to potentially impacted PWS, focusing primarily on source wells. PFAS detections above the required reporting limit (4 ng/L for PFAS included in the final analysis) were used to assess associations with serum PFAS levels. Results Out of 563 participants in Southern California included in the final analysis, 314 (56%) lived in a PWS service area with at least one PFAS detected in their untreated source water and/or treated drinking water. Serum perfluorohexane sulfonic acid (PFHxS) geometric mean concentrations were 31.9% (95% CI: 11.1–56.6%) higher among participants whose PWS had at least one PFHxS detection compared to those without detectable levels. For participants with post-treatment drinking water data (n = 235), serum PFAS geometric mean concentrations were higher compared to those without detections for all modeled PFAS: PFHxS 79.9% (38.3–133.9%), perfluorooctanoic acid (PFOA) 30.4% (5.5–61.2%), perfluorooctane sulfonic acid (PFOS) 31.2% (0.7–70.9%), and ∑5 PFAS 42.0% (14.5–76.1%). Impact This study examined the association between public water system PFAS detections and serum concentrations among a general population of Southern California adults. We found that PFAS detections in public water systems were associated with higher serum PFAS concentrations. Our findings suggest PFAS contamination in drinking water may be a significant contributor to serum PFAS levels, even among communities without high level contamination from industrial manufacturing. These results support drinking water monitoring initiatives in California to understand PFAS contamination and mitigate exposure.

Verified
Journal Article
Open access
PDF file
SSStanley Sciortino
Stanley Sciortino
SGSteve Graham
Steve Graham
TFToki Fillman
Toki Fillman
HKHari Kandasamy
Hari Kandasamy
RCRobin Cooley
Robin Cooley
PRPeter Robinson
Peter Robinson
To investigate COVID-19 surveillance among pregnant women, the California Genetic Disease Screening Program conducted a screening performance and seroprevalence evaluation of maternal SARS-CoV-2 antibodies detected in banked newborn dried blood spots (DBS). We obtained seropositive results for 2890 newborn DBS from cohorts in 2020 and 2021 using Enable Bioscience’s Antibody Detection by Agglutination-PCR (ADAP) assay for SARS-CoV-2 antibodies. To infer maternal infection, we linked 312 women with a known laboratory-confirmed COVID-19 episode with their newborn’s DBS SARS-CoV-2 antibody result. Among 2890 newborns, we detected 453 (15.7%) with SARS-CoV-2 antibodies in their DBS. Monthly snapshot statewide seroprevalence among neonates was 12.2% (95% CI 10.3–14.1%, n =1156) in December 2020 and 33.3% (95% CI 29.1–37.4%, n = 26) in March 2021. The longest time recorded from COVID-19 infection to a seropositive neonatal result was 11.7 months among the 312 mothers who had an available SARS-CoV-2 PCR test result. Approximately 94% (153/163) of DBS were seropositive when a known maternal infection occurred earlier than 19 days before birth. The estimated relative sensitivity of DBS to identify prevalent maternal infection was 85.1%, specificity 98.5% and PPV 99.2% (n = 312); the sensitivity was lowest during the December 2021 surge when many infections occurred within 19 days of birth. Fifty pre-pandemic specimens (100% seronegative) and 23 twin-pair results (100% concordant) support an intrinsic specificity and PPV of ADAP approaching 100%. Maternal infection surveillance is limited by a time lag prior to delivery, especially during pandemic surges.